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The availability of new and more effective disease modifying therapies (DMTs) for treating relapsing 
forms of multiple sclerosis (MS) is challenging the old paradigm of simply reducing relapse rates and 
the consequences of relapses. Data has emerged which shows that both relapses and ongoing focal 
inflammatory activity on MRI (new or enlarging T2-lesions and gadolinium (Gd)-enhancing lesions) 
are associated with a worse short to intermediate-term prognosis, contradicting oft-quoted natural 
history studies (1, 2). Moreover, why the prognosis of relapses and subclinical MRI activity on DMTs 
differs from that seen on placebo-treatment, or in natural history studies of MS, fundamentally 
questions the role of focal inflammatory lesions in the pathogenesis of relapsing MS (2).  As a result 
of these observations MSologists are redefining their primary aim of treatment as now being ‘no 
evident disease activity’ (NEDA) (3).  At present, NEDA is a composite of three related measures of 
disease activity: (i) no relapses, (ii) no disability progression and (iii) no MRI activity (new or enlarging 
T2 lesions or Gd-enhancing lesions, which in our view represent “subclinical relapses”) (4, 5) and is 
derived from the post-hoc analyses of contemporary phase 3 clinical trials, for example natalizumab 
and cladribine (4, 5).  
NEDA is an important goal for treating individual patients with relapsing disease, and potentially as 
an outcome in future clinical trials (6). The problem with the latter is that until MRI activity is 
accepted as a surrogate marker of CNS inflammatory activity by regulators, NEDA is unlikely to be 
used as a primary outcome in clinical trials. However, what about using NEDA as a treatment goal in 
clinical practice? Before you can adopt NEDA in day-to-day clinical practice you need to decide when 
to ‘rebaseline’ treated patients and how frequently MRI studies need to be performed as most DMTs 
take several weeks or months to have an appreciable effect. We therefore suggest that patients 
starting on DMT have a new baseline MRI after the onset of action of the DMT. The timing of the 
baseline MRI should be based on the pharmacodynamics of the DMT concerned; it simply needs to 
occur after a period of time when we are confident that the drug has had a sufficient period of time 
to start working. Therefore any disease activity destined to happen in the weeks or months after 
starting a therapy, before the DMT is effective, will be counted as disease activity that is 
unresponsive to treatment. For example, with natalizumab therapy the proportion of patients with 
NEDA increases from 51% in year one to 70% in year two when the trial participants were 
rebaselined at 12 months (5). For interferon-beta, teriflunomide, dimethyl fumarate and 
natalizumab we would recommend rebaselining at 3 to 6 months, for glatiramer acetate 9 to 12 
months, and for alemtuzumab approximately 12 months after the last course of infusions, or 24 
months after the initial start of treatment. Please note the disparity in time for glatiramer acetate 
and alemtuzumab. Serial MRI studies have indicated that glatiramer acetate reaches its peak level of 
activity on MRI after 7 months hence the recommendation to rebaseline beyond this time point (7). 
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The rules for induction therapy are different to that of escalation. In the case of an induction agent 
such as alemtuzumab, which is given as a course of five consecutive days infusions in year 1 and 
three consecutive days infusions in year 2, breakthrough disease activity is used as an indicator to 
retreat rather than to switch therapy; therefore there is little point in doing a rebaselining MRI until 
after the second course of therapy has had a chance to work and is close enough to the time when a 
third, or subsequent course, can be given if deemed necessary (8). The question of how many annual 
cycles need to be given before considering that a person has failed alemtuzumab, or another 
induction, therapy is open to argument. In the 7-year follow-up study of 87 subjects treated as part 
of the open-label alemtuzumab cohort in Cambridge, 45 (52%) received just the two planned cycles 
of alemtuzumab 12 months apart (9). Further cycles were only offered if a relapse occurred: 31 
patients (36%) received three cycles; seven patients (8%) four cycles; and only one patient five cycles 
(9). Based on these data it seems as if the majority of patients respond, at least clinically, in the 
intermediate term to alemtuzumab therapy. We would therefore consider breakthrough activity 
beyond five cycles of alemtuzumab therapy a treatment failure and patients should then be 
considered for alternative therapies.  
We recommend doing both a FLAIR, T2 and Gd-enhanced T1 MRI; if there are Gd-enhancing lesions 
on the rebaselining MRI, indicative of a subclinical relapse, this would indicate that there is 
breakthrough disease and a need to switch treatment, or in the case of alemtuzumab, and other 
induction agents, to have a repeat course of therapy.  Please note that the timing of the rebaselining 
MRI is not set in stone and will be influenced by pragmatic local considerations, such as the 
availability of MRI. It is important that if you do implement a local strategy of treating to the target 
of NEDA that you involve your neuroradiology colleagues. Looking for new, or enlarging, T2-lesions 
requires neuroradiologists to be diligent in how they compare and report MRI studies, which is 
different to diagnostic studies (10) .  
NEDA raises another issue in relation to whether or not the underlying treatment strategy is an 
induction or maintenance therapy. Disease activity on a maintenance therapy, provided the patient 
has been adherent to treatment, can be interpreted as a sub-optimal or non-response (1). In 
contrast, disease activity on an induction therapy, for example alemtuzumab, is generally considered 
as being an indication to retreat the patient (8, 11, 12).  
A potential criticism of NEDA is the inclusion of disease progression, separate to that of incomplete 
recovery from relapses, as a component of the composite. Progressive disability in the absence of 
relapses may have little to do with ongoing focal inflammatory activity and may simply represent a 
dying back central axonopathy as a result of preceding focal inflammatory lesions (3). This process is 
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often referred to as post-inflammatory neurodegeneration, or non-relapsing progressive MS, and 
underpins the so-called two-stage disease hypothesis (13, 14). As age is one of the most powerful 
predictors of the onset of this phase of the disease, it is reasonable to hypothesise that ageing may 
be contributing to disability accrual during the non-relapsing deteriorating phase of MS (15). It 
remains uncertain whether or not this stage of the disease can be modified with current 
immunomodulatory therapies, and some colleagues will no doubt feel uncomfortable to switching, 
or stopping a DMT, based on non-relapse associated increase in disability alone. There is a strong 
argument for not including non-relapsing disability progression as part of the definition of NEDA. We 
anticipate data from ongoing extension and registry studies will clarify this point. 
We predict that the definition of NEDA will evolve with technological innovations and clinical 
practice. A future definition of NEDA will likely need to include patient-related outcome measures 
(PROs or PROMS), focal grey matter disease activity, a whole and/or a regional brain atrophy metric 
and possibly fluid biomarkers, for example cerebrospinal fluid neurofilament levels (16, 17). 
Importantly, a recent meta-analysis by Sormani and colleagues (18) demonstrates that both focal 
inflammatory lesions, as measured by increased T2-lesion load over 2-years, and 
neurodegeneration, measured using whole brain volume loss in year two, explained 75% of the 
variance of disability progression over 2 years on DMT, which was better than either metric alone.  
Therefore, it would seem appropriate to include some metric to indicate the slowing or 
normalisation of brain atrophy rates in future definitions of NEDA. This is particularly pertinent now 
that we have therapies that have been shown reduce the rate of brain atrophy in treated patients 
(11, 12, 19-21). Of note, Sormani and colleagues (18) deliberately removed brain volume changes 
during year one from their meta-analysis to exclude the so-called ‘pseudoatrophy’ effect, resulting 
from the reduced inflammatory activity and associated oedema when anti-inflammatory agents are 
initiated in people with active MS (22). 
Some commentators are very critical of NEDA as a treatment target and feel we need to be more 
pragmatic; they claim that a zero tolerance target would mean the majority of patients would end 
up being on ‘more risky’ high efficacy therapies. Hence they are promoting a strategy that allows 
some disease activity using for example the Rio (23), or modified Rio (24), scores as a treatment 
target. Our argument is that if you accept the science supporting the concept that ‘focal 
inflammation is bad’ for MS and that inflammation is associated with poor short, intermediate and 
long-term outcomes, then if the majority of patients end up on the so-called ‘risky high-efficacy’ 
therapies because of breakthrough activity, then this is what they require to treat their MS. 
Induction of long-term remission or, NEDA, is the treatment target in rheumatoid arthritis (25), 
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inflammatory bowel disease (26) and other organ-specific autoimmune diseases; why would we 
want to treat MS differently compared to these other inflammatory diseases?  
Recent evidence indicates that patients with MS treated-to-target of NEDA do better than those 
with breakthrough disease (at a clinical or subclinical level).  We therefore encourage MSologists to 
implement NEDA as a principal aim in the management of relapsing MS.  Figure 1 is a flowchart of 
how we have implemented treat-2-target of NEDA at our institution.  The important take-home 
message is that the treatment goals in MS have moved and now require the setting of targets and 
active monitoring of outcomes. Finally, there is an evident need to regularly update the definition of 
NEDA as new technologies become available and are validated as predictors of a treatment 
response; we envisage this definition changing in the near future to include a brain volume metric.  
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Legends 
Figure 1: Treatment algorithm for implementing a treat-2-target strategy for the management of 
disease-modifying therapies in patients with active multiple sclerosis  
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1. The new treatment target in relapsing MS is NEDA 
2. To target NEDA requires a rebaselining MRI  
3. Disease activity on a maintenance therapy indicates a sub-optimal response 
4. Disease activity on an induction therapy is an indication to retreat 
5. The NEDA definition will evolve with technological innovations 
 
